{"created":"2023-07-25T09:15:48.899082+00:00","id":15823,"links":{},"metadata":{"_buckets":{"deposit":"f8da8851-2183-4bac-bcd5-5519ef6705a9"},"_deposit":{"created_by":27,"id":"15823","owners":[27],"pid":{"revision_id":0,"type":"depid","value":"15823"},"status":"published"},"_oai":{"id":"oai:toyama.repo.nii.ac.jp:00015823","sets":["439:440:441:442"]},"author_link":["168042","168048","168045","168049","5960","168052","5946","168047","41305","168050","168044","168046","168051","5948"],"item_2_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-05","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"778","bibliographicPageStart":"774","bibliographicVolumeNumber":"4","bibliographic_titles":[{},{"bibliographic_title":"Molecular and clinical oncology"}]}]},"item_2_description_15":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to prolong survival in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR-TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression-free survival (6.2 vs. 13.2 months; P<0.01) and overall survival (10.5 vs. 36.1 months; P<0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression-free survival (P=0.05) and overall survival (P<0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. Close observation is required in EGFR mutation-positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR-TKIs.","subitem_description_type":"Abstract"}]},"item_2_description_40":{"attribute_name":"資源タイプ(DSpace)","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_2_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"出版社サイトへのリンク：https://doi.org/10.3892/mco.2016.779","subitem_description_type":"Other"}]},"item_2_description_6":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Mol Clin Oncol. 2016 May;4(5):774-778. ","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Spandidos Publications"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"27123277","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"info:doi/10.3892/mco.2016.779","subitem_relation_type_select":"DOI"}}]},"item_2_source_id_8":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2049-9450","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Inomata, Minehiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hayashi, Ryuji"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Tanaka, Hiroaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimokawa, Kazuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tokui, Kotaro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taka, Chihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okazawa, Seisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kambara, Kenta"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichikawa, Tomomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamada, Toru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miwa, Toshiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kashii, Tatsuhiko"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Matsui, Shoko"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Tobe, Kazuyuki"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-03-07"}],"displaytype":"detail","filename":"MolClinOnclo_4(5)_774to778_Inomata.pdf","filesize":[{"value":"361.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"MolClinOnclo_4(5)_774to778_Inomata","url":"https://toyama.repo.nii.ac.jp/record/15823/files/MolClinOnclo_4(5)_774to778_Inomata.pdf"},"version_id":"fc74a108-a03e-4beb-9d79-a2a5465bb60f"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib."},{"subitem_title":"Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.","subitem_title_language":"en"}]},"item_type_id":"2","owner":"27","path":["442"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-03-07"},"publish_date":"2018-03-07","publish_status":"0","recid":"15823","relation_version_is_last":true,"title":["Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib."],"weko_creator_id":"27","weko_shared_id":27},"updated":"2023-07-25T13:11:58.108265+00:00"}